Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GUBRA.CO
- Price
- 530.50
- Stock movement down
- -9.00 (-1.67%)
- Company name
- Gubra A/S
- Exchange
- (CO ,
- Currency
- DKK )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 8.65B
- Ent værdi
- 8.75B
- Pris/omsætning
- 38.65
- Pris/bog
- 18.65
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -0.38%
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- 50.71%
- 3 års afkast
- -
- 5 års afkast
- -
- 10 års afkast
- -
Senest opdateret: 2025-06-22
UDBYTTE
GUBRA.CO betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 38.65 |
| Pris til egenkapital | 18.65 |
| EV i forhold til salg | 39.10 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 16.31M |
| EPS (TTM) | -2.77 |
| FCF pr. aktie (TTM) | -0.22 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 223.81M |
| Bruttofortjeneste (TTM) | 131.47M |
| Driftsindkomst (TTM) | -51.04M |
| Nettoindkomst (TTM) | -46.53M |
| EPS (TTM) | -2.77 |
| EPS (1 år frem) | - |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 58.74% |
| Driftsmargin (TTM) | -22.80% |
| Fortjenstmargin (TTM) | -20.79% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 46.91M |
| Nettotilgodehavender | 31.07M |
| Omsætningsaktiver i alt | 492.26M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 13.83M |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 610.76M |
| Kreditor | 14.81M |
| Kortfristet/nuværende langsigtet gæld | 91.46M |
| Summen af kortfristede forpligtelser | 67.99M |
| Sum gæld | 146.88M |
| Aktionærernes egenkapital | 463.88M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -25.39M |
| Investeringsudgifter (TTM) | 18.77M |
| Fri pengestrøm (TTM) | -3.66M |
| Udbetalt udbytte (TTM) | 14.00K |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -10.03% |
| Afkast af aktiver | -7.62% |
| Afkast af investeret kapital | -9.75% |
| Kontant afkast af investeret kapital | -0.77% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 539.50 |
| Daglig høj | 543.00 |
| Daglig lav | 529.00 |
| Daglig volumen | 40K |
| Højeste gennem alle tider | 728.00 |
| 1 års analytiker estimat | 800.00 |
| Beta | - |
| EPS (TTM) | -2.77 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 21 Aug 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| GUBRA.CO | S&P500 | |
| Nuværende prisfald fra top notering | -27.13% | -3.04% |
| Højeste prisfald | -52.03% | -56.47% |
| Højeste efterår dato | 22 Apr 2025 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -15.47% | -11.04% |
| Gennemsnitlig tid til nyt højdepunkt | 11 days | 12 days |
| Maks. tid til nyt højdepunkt | 121 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
8.65B
Markedsværdi kategori
Mid-cap
Beskrivelse
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally. The company operates through CRO, Discovery & Partnerships, and Gubra Green segments. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, assays and molecular pharmacology, bioinformatics, bioanalysis, next gen sequencing, and 2D and 3D imaging. The company has a partnership and collaboration with Boehringer Ingelheim to discover novel peptides for the treatment of obesity. Gubra A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Personale
235
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Denmark
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
HØRSHOLM, DK / ACCESS Newswire / June 3, 2025 / Gubra (CPH:GUBRA) Notice to convene extraordinary GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND GUBRA A/SCVR NO. 30 51 40 41 To the shareholders of G...
3. juni 2025
HØRSHOLM, DK / ACCESS Newswire / May 9, 2025 / Gubra (CPH:GUBRA) - Today, Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement t...
9. maj 2025
HØRSHOLM, DK / ACCESS Newswire / April 3, 2025 / Gubra (CPH:GUBRA) Following Gubra's Annual General Meeting 2025 taking place earlier today we are pleased to confirm some exciting changes to the Board...
3. april 2025
HØRSHOLM, DK / ACCESS Newswire / April 3, 2025 / Gubra (CPH:GUBRA) On Thursday, 3 April 2025 at 10:00 am (CEST), the annual general meeting of Gubra A/S (the "Company") was held at the Company's regis...
3. april 2025
HØRSHOLM, DK / ACCESS Newswire / April 1, 2025 / Gubra (CPH:GUBRA): With reference to Gubra's A/S (CPSE:GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for...
1. april 2025
HØRSHOLM, DK / ACCESS Newswire / April 1, 2025 / Gubra (CPH:GUBRA) GUBamy was well tolerated with adverse events being predominantly GI related, mild and consistent with data from the SAD study. Doses...
1. april 2025
HØRSHOLM, DK / ACCESS Newswire / March 28, 2025 / Gubra (CPH:GUBRA) With reference to AbbVie's (NYSE:ABBV) and Gubra A/S' (CPSE:GUBRA) joint announcement of March 3, 2025 regarding a license agreement...
28. marts 2025
HØRSHOLM, DK / ACCESS Newswire / March 10, 2025 / Gubra (CPH:GUBRA) Notice to convene ANNUAL GENERAL MEETING 2025 GUBRA A/SCVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), n...
10. marts 2025
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
HØRSHOLM, DK / ACCESS Newswire / March 03, 2025 / Gubra (CPH:GUBRA) Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide d...
3. marts 2025